ZA200300287B - Indole derivatives useful for the treatment of CNS disorders. - Google Patents
Indole derivatives useful for the treatment of CNS disorders. Download PDFInfo
- Publication number
- ZA200300287B ZA200300287B ZA200300287A ZA200300287A ZA200300287B ZA 200300287 B ZA200300287 B ZA 200300287B ZA 200300287 A ZA200300287 A ZA 200300287A ZA 200300287 A ZA200300287 A ZA 200300287A ZA 200300287 B ZA200300287 B ZA 200300287B
- Authority
- ZA
- South Africa
- Prior art keywords
- indole
- piperidin
- ethyl
- chloro
- methylphenyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 16
- 150000002475 indoles Chemical class 0.000 title claims description 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 title description 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- -1 cyano, nitro, amino, hydroxy Chemical group 0.000 claims description 121
- 150000001875 compounds Chemical class 0.000 claims description 46
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 9
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 230000016571 aggressive behavior Effects 0.000 claims description 3
- 239000000164 antipsychotic agent Substances 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 230000007958 sleep Effects 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- DPMGFJCRVWDBHF-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]oxane-4-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1CCOCC1 DPMGFJCRVWDBHF-UHFFFAOYSA-N 0.000 claims description 2
- KIXJKVGKALVEBC-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C(CCN2CC=C(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 KIXJKVGKALVEBC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000003441 thioacyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- SZCVKMOVEPYVAY-UHFFFAOYSA-N 3-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-1-methyl-1-phenylurea Chemical compound C=1C=C(C)C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)=CC=1NC(=O)N(C)C1=CC=CC=C1 SZCVKMOVEPYVAY-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- SYBVOKCVTYSRPG-UHFFFAOYSA-N n-[3-[2-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(CCN3CCC(CC3)C=3C4=CC(Cl)=CC=C4NC=3)C(C)=CC=2)=C1 SYBVOKCVTYSRPG-UHFFFAOYSA-N 0.000 claims 1
- XQICOXCELYJLLR-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(CCN3CCC(CC3)C=3C4=CC=C(Cl)C=C4NC=3)C(C)=CC=2)=C1 XQICOXCELYJLLR-UHFFFAOYSA-N 0.000 claims 1
- SPOFUJQNHLVFOS-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 SPOFUJQNHLVFOS-UHFFFAOYSA-N 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 30
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 26
- 229960003638 dopamine Drugs 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 6
- 230000000561 anti-psychotic effect Effects 0.000 description 5
- 230000002301 combined effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- QZOPRMWFYVGPAI-UHFFFAOYSA-N 1-chloroindole Chemical compound C1=CC=C2N(Cl)C=CC2=C1 QZOPRMWFYVGPAI-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- OZMNONYSCNSFPO-UHFFFAOYSA-N 3-cyclohexyl-n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]propanamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)CCC1CCCCC1 OZMNONYSCNSFPO-UHFFFAOYSA-N 0.000 description 1
- DSKIXYWEEZMPKP-UHFFFAOYSA-N 4-chloro-n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]benzamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 DSKIXYWEEZMPKP-UHFFFAOYSA-N 0.000 description 1
- UPWHNYKFYLPTLY-UHFFFAOYSA-N 4-fluoro-n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]benzamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=C(F)C=C1 UPWHNYKFYLPTLY-UHFFFAOYSA-N 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002539 anti-aggressive effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- XDPFARVEOFULEU-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 XDPFARVEOFULEU-UHFFFAOYSA-N 0.000 description 1
- NIFCQXBHZRSABD-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(CCN3CCC(CC3)C=3C4=CC(F)=CC=C4NC=3)C(C)=CC=2)=C1 NIFCQXBHZRSABD-UHFFFAOYSA-N 0.000 description 1
- PXWRAGRXMNGNBJ-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclopropanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1CC1 PXWRAGRXMNGNBJ-UHFFFAOYSA-N 0.000 description 1
- YWXFDVJNZFOOMK-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]hexanamide Chemical compound CCCCCC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 YWXFDVJNZFOOMK-UHFFFAOYSA-N 0.000 description 1
- HIMBSTFPSOTMBD-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 HIMBSTFPSOTMBD-UHFFFAOYSA-N 0.000 description 1
- TYYBWXCYEWIXCL-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-7h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CC=C(CC2)C=2C3=CC(F)=CCC3=NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 TYYBWXCYEWIXCL-UHFFFAOYSA-N 0.000 description 1
- GDWYHPJDBGGMAY-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 GDWYHPJDBGGMAY-UHFFFAOYSA-N 0.000 description 1
- GAJNABYGFQNROT-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)CC1=CC=C(F)C=C1 GAJNABYGFQNROT-UHFFFAOYSA-N 0.000 description 1
- XHNCUDFWPYXDNO-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-phenylpropanamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)CCC1=CC=CC=C1 XHNCUDFWPYXDNO-UHFFFAOYSA-N 0.000 description 1
- GDDHTDLBSUZWCA-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 GDDHTDLBSUZWCA-UHFFFAOYSA-N 0.000 description 1
- ICOKBOHVIJCZKC-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclopropanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1CC1 ICOKBOHVIJCZKC-UHFFFAOYSA-N 0.000 description 1
- GQVIKVMHMCRODW-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiadiazole-5-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CN=NS1 GQVIKVMHMCRODW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- WUHLVXDDBHWHLQ-UHFFFAOYSA-N pentazole Chemical group N=1N=NNN=1 WUHLVXDDBHWHLQ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000002265 phtalazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001123 | 2000-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300287B true ZA200300287B (en) | 2004-03-02 |
Family
ID=8159625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300287A ZA200300287B (en) | 2000-07-21 | 2003-01-10 | Indole derivatives useful for the treatment of CNS disorders. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6743809B2 (cs) |
| EP (1) | EP1305307B1 (cs) |
| JP (1) | JP2004504396A (cs) |
| KR (1) | KR100851793B1 (cs) |
| CN (1) | CN1264838C (cs) |
| AR (1) | AR029858A1 (cs) |
| AT (1) | ATE266024T1 (cs) |
| AU (2) | AU2001281738B2 (cs) |
| BG (1) | BG107528A (cs) |
| BR (1) | BR0112998A (cs) |
| CA (1) | CA2416212C (cs) |
| CZ (1) | CZ301114B6 (cs) |
| DE (1) | DE60103162T2 (cs) |
| EA (1) | EA004749B1 (cs) |
| ES (1) | ES2219554T3 (cs) |
| HR (1) | HRP20030015A2 (cs) |
| HU (1) | HUP0302820A3 (cs) |
| IL (2) | IL153605A0 (cs) |
| IS (1) | IS2172B (cs) |
| MX (1) | MXPA02012927A (cs) |
| NO (1) | NO323799B1 (cs) |
| NZ (1) | NZ523436A (cs) |
| PT (1) | PT1305307E (cs) |
| SK (1) | SK286701B6 (cs) |
| TR (1) | TR200401488T4 (cs) |
| UA (1) | UA73995C2 (cs) |
| WO (1) | WO2002008223A1 (cs) |
| ZA (1) | ZA200300287B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ547314A (en) | 2003-11-17 | 2010-02-26 | Boehringer Ingelheim Int | Novel piperidine-substituted indoles- or hetero-derivatives thereof and their use as modulators of chemokine receptor (CCR-3) |
| TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
| CA2606550C (en) | 2005-04-30 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Piperidine-substituted indoles |
| EP2079725B1 (en) | 2006-10-27 | 2011-12-14 | Boehringer Ingelheim International GmbH | Piperidyl-propane-thiol ccr3 modulators |
| CN101486654B (zh) * | 2009-03-04 | 2012-10-10 | 西安近代化学研究所 | 2-甲基-3-硝基苯乙酸合成方法 |
| CN110041318B (zh) * | 2018-01-17 | 2022-07-29 | 中国科学院上海药物研究所 | 一类多巴胺d5受体激动剂及其制备和应用 |
| CN110498789B (zh) * | 2018-05-17 | 2022-04-05 | 上海医药工业研究院 | 芳烷哌啶类衍生物及其在多靶点抗抑郁症中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2322470A1 (de) * | 1973-05-04 | 1974-11-21 | Boehringer Sohn Ingelheim | Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung |
| AT332401B (de) * | 1973-11-26 | 1976-09-27 | Roussel Uclaf | Verfahren zur herstellung von neuen (4'-(3''-indolyl)-piperidino)-alkylarylketonderivaten |
| ATE92057T1 (de) * | 1987-08-13 | 1993-08-15 | Glaxo Group Ltd | Indol-derivate. |
| GB8719167D0 (en) | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| WO1994003444A1 (en) * | 1992-08-05 | 1994-02-17 | John Wyeth & Brother Limited | Amide derivatives |
| ES2094653T3 (es) * | 1993-04-22 | 1997-01-16 | Pfizer Res & Dev | Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña. |
| ES2063700B1 (es) * | 1993-04-28 | 1995-07-16 | Vita Invest Sa | Agente activo sobre el sistema nervioso central, proceso para su preparacion y composiciones farmaceuticas que lo contengan. |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
-
2001
- 2001-07-17 EA EA200300179A patent/EA004749B1/ru not_active IP Right Cessation
- 2001-07-17 MX MXPA02012927A patent/MXPA02012927A/es active IP Right Grant
- 2001-07-17 PT PT01960182T patent/PT1305307E/pt unknown
- 2001-07-17 HU HU0302820A patent/HUP0302820A3/hu unknown
- 2001-07-17 EP EP01960182A patent/EP1305307B1/en not_active Expired - Lifetime
- 2001-07-17 AT AT01960182T patent/ATE266024T1/de not_active IP Right Cessation
- 2001-07-17 AU AU2001281738A patent/AU2001281738B2/en not_active Ceased
- 2001-07-17 JP JP2002514129A patent/JP2004504396A/ja active Pending
- 2001-07-17 AU AU8173801A patent/AU8173801A/xx active Pending
- 2001-07-17 SK SK203-2003A patent/SK286701B6/sk not_active IP Right Cessation
- 2001-07-17 IL IL15360501A patent/IL153605A0/xx unknown
- 2001-07-17 CZ CZ20030196A patent/CZ301114B6/cs not_active IP Right Cessation
- 2001-07-17 CA CA002416212A patent/CA2416212C/en not_active Expired - Fee Related
- 2001-07-17 UA UA2003010167A patent/UA73995C2/uk unknown
- 2001-07-17 ES ES01960182T patent/ES2219554T3/es not_active Expired - Lifetime
- 2001-07-17 CN CNB018151078A patent/CN1264838C/zh not_active Expired - Fee Related
- 2001-07-17 DE DE60103162T patent/DE60103162T2/de not_active Expired - Fee Related
- 2001-07-17 BR BR0112998-8A patent/BR0112998A/pt not_active IP Right Cessation
- 2001-07-17 HR HR20030015A patent/HRP20030015A2/hr not_active Application Discontinuation
- 2001-07-17 KR KR1020037000850A patent/KR100851793B1/ko not_active Expired - Fee Related
- 2001-07-17 NZ NZ523436A patent/NZ523436A/en unknown
- 2001-07-17 TR TR2004/01488T patent/TR200401488T4/xx unknown
- 2001-07-17 WO PCT/DK2001/000507 patent/WO2002008223A1/en not_active Ceased
- 2001-07-20 AR ARP010103457A patent/AR029858A1/es unknown
-
2002
- 2002-12-23 IS IS6663A patent/IS2172B/is unknown
- 2002-12-24 IL IL153605A patent/IL153605A/en not_active IP Right Cessation
-
2003
- 2003-01-10 ZA ZA200300287A patent/ZA200300287B/en unknown
- 2003-01-10 NO NO20030127A patent/NO323799B1/no not_active IP Right Cessation
- 2003-01-17 US US10/347,574 patent/US6743809B2/en not_active Expired - Fee Related
- 2003-02-05 BG BG107528A patent/BG107528A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2551875T3 (es) | Agentes nuevos contra la malaria | |
| CN102858742B (zh) | 具有二环部分的trpv1香草酸受体拮抗剂 | |
| EP1233959B1 (en) | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | |
| JPWO2009107391A1 (ja) | ６員芳香環含有化合物 | |
| HU230787B1 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
| ZA200300287B (en) | Indole derivatives useful for the treatment of CNS disorders. | |
| US7105543B2 (en) | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| AU2001281738A1 (en) | Indole derivatives useful for the treatment of cns disorders | |
| AU2001273883A1 (en) | Indole derivatives useful for the treatment of cns disorders | |
| JP2025537555A (ja) | キノリンアミド構造を有するイソインドリノン誘導体及びその用途 | |
| TW202523319A (zh) | 小分子化合物或其鹽類或該等的溶劑合物、含其之gnaq抑制劑與醫藥組成物以及其用途 |